血清/胸腔积液 CEA、CA125、NSE 联检对肺癌诊断的价值

目的:探讨血清和胸腔积液中CEA、CA125、NSE联检对肺癌诊断的价值.方法:用放射免疫分析检测88例肺癌和100例炎性胸腔积液患者血清、胸腔积液以及50例健康对照组人员血清CEA、CA125和NSE含量.结果:肺癌组血清(胸腔积液)CEA、CA125、NSE含量和阳性率均高于炎性胸腔积液患者和健康对照组人员(P＜0.05),炎性组血清CA125比健康对照组高(P＜0.05).88例肺癌患者血清三项肿瘤标志物联检阳性率为70.5%,胸腔积液中阳性率79.5%,联合血清、胸腔积液阳性率为90.9%.结论:联检能提高肺癌的诊断率,提倡联检.

Clinical Value of Combined Determination of Serum and Hydrothorax Fluid Levels of CEA, CA125, NSE in the Diagnosis of Lung Cancer

Objective To study the clinical value of combined determination of CEA, CA125, NSE levels both in serum and hydrothorax fluid in the diagnosis of lung cancer. Methods Serum and hydrothorax fluid levels of CEA, CA125, NSE were determined with RIA in 88 patients with lung cancers, 100 patients with inflammatory hydrothorax, and 50 controls. Results The levels of serum and hydrothorax fluid CEA, CA125, NSE in lung cancer patients were significantly higher than those in patients with inflammatory hydrothorax and controls (P<0.05). In lung cancer group, the positive rate of combined detection of serum CEA, CA125, NSE was 70.5%, the positive rate of combined detection of hydrothorax fluid CEA, CA125, NSE was 79.5% and the positive rate of combined detection of serum and hydrothorax fluid three kinds of tumor markers was 87.5%. Conclusion Combined detection of serum and hydrothuax fluid levels of CEA, CA125, NSE is to be advocated because of higher sensitivity for diagnosis of lung cancer.